SPERO THERAP.INC. DL-,001

Based on the positive results of the registrational Phase 3 PIVOT-PO study, Tebipenem is expected to be approved under the SPA in mid-2026. Spero will not bear any costs or risks since GSK, as a license partner, will take over commercialization. Approval is expected to trigger in total of $175 million in milestone payments over the next 12 months.» Mehr auf seekingalpha.com

Squarepoint Ops LLC bought a new stake in Spero Therapeutics, Inc. (NASDAQ:SPRO – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 55,051 shares of the company’s stock, valued at approximately $57,000. Squarepoint Ops LLC owned approximately 0.10% of Spero Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Other institutional investors and hedge funds also recently made changes to their positions in the company. Monimus Capital Management LP acquired a new position in Spero Therapeutics during the fourth quarter worth $320,000. Renaissance Technologies LLC boosted its holdings in Spero Therapeutics by 13.4% during the fourth quarter. Renaissance Technologies LLC now owns 1,105,591 shares of the company’s stock worth $1,139,000 after purchasing an additional 130,938 shares during the last quarter. Anson Funds Management LP boosted its holdings in Spero Therapeutics by 2.4% during the fourth quarter. Anson Funds Management LP now owns 3,839,886 shares of the company’s stock worth $3,955,000 after purchasing an additional 89,436 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Spero Therapeutics by 26,011.9% during the fourth quarter. JPMorgan Chase & Co. now owns 61,624 shares of the company’s stock worth $63,000 after purchasing an additional 61,388 shares during the last quarter. Finally, ADAR1 Capital Management LLC boosted its holdings in Spero Therapeutics by 7.8% during the fourth quarter. ADAR1 Capital Management LLC now owns 801,277 shares of the company’s stock worth $825,000 after purchasing an additional 57,818 shares during the last quarter. Institutional investors and hedge funds own 25.60% of the company’s stock. Spero Therapeutics Trading Up 3.3% NASDAQ SPRO opened at $2.85 on Wednesday. The firm’s fifty day moving average price is $1.04 and its two-hundred day moving average price is $0.96. Spero Therapeutics, Inc. has a 1 year low of $0.51 and a 1 year high of $2.95. The firm has a market capitalization of $159.35 million, a P/E ratio of 40.72 and a beta of 1.31. Spero Therapeutics (NASDAQ:SPRO – Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.30. Spero Therapeutics had a net margin of 3.30% and a return on equity of 4.03%. The business had revenue of $5.87 million for the quarter, compared to analyst estimates of $11.00 million. On average, research analysts anticipate that Spero Therapeutics, Inc. will post -1.2 EPS for the current fiscal year. About Spero Therapeutics (Free Report) Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.» Mehr auf defenseworld.net

SPRO shares surge after GSK-partnered oral drug hits phase III goal early, paving the way for FDA filing and a shift in cUTI treatment options.» Mehr auf zacks.com